Refine by
Tumor Mutation Suppliers & Manufacturers
12 companies found
based inSeoul, SOUTH KOREA
We detect and analyze genomic profile of tumor DNA with a single draw of blood. With this comprehensive profile, we provide personalized and optimized analysis information that can be utilized in therapy selection and monitoring. Ultimately, we ...
Cell-free DNA (cfDNA) is circulating fragments of DNA that is released from cells into the circulatory system throughout the body. Tumor cells also release DNA into the blood stream, which is called circulation-tumor DNA(ctDNA). IMBdx Inc.’s ...
based inGosselies, BELGIUM
We are a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases. OncoDNA is a company specializing in precision for the treatment of cancer and other genetic diseases. We are ...
Oncodeep® is a comprehensive biomarker test designed to guide treatment of advanced, metastatic solid tumors. When your patients are diagnosed with a rare cancer type or an aggressive cancer, when chemotherapy doesn't work or when cancer comes ...
based inOxford, UNITED KINGDOM
Oxford Vacmedix was established in 2012 as a spinout from Oxford University. Its aim is to develop therapeutic agents for the treatment of cancer based on the invention of Professor Shisong Jiang – Recombinant Overlapping Peptides (ROP). These ...
based in, MASSACHUSETTS (USA)
MtoZ Biolabs is an integrate contract research organization (CRO) providing advanced proteomics, metabolomics, bioinformatics, and biopharmaceutical analysis services to researchers in biochemistry, biotechnology, and biopharmaceutical fields. The ...
The immunopeptidome comprises all short peptides presented on the cell surface by HLA-I and II molecules for T-cell recognition. Immunopeptidomics analysis aims to explore the dynamics and composition of both type I and II immune peptides. ...
based inBoston, MASSACHUSETTS (USA)
SOPHiA GENETICS is the creator of a global data-sharing network – we work with customers from over 790 institutions in over 70 countries. Our network advances data-driven medicine to improve health outcomes and economics worldwide. We offer a ...
Deeper genomic insights, fewer missed opportunities. CGP enables clinical researchers to identify actionable variants and biomarkers across hundreds of genes using a single solution. The SOPHiA DDMTM Platform offers decentralized, in-house next ...
based inMontpellier, FRANCE
SeqOne Genomics is a startup based in Montpellier in the South of France, founded in 2017. The company develops state-of-the-art genomics analysis tools for clinical applications in the fields of cancer and rare diseases. Its flagship product, ...
Genetic cancer analyses are particularly challenging due to the huge number of de novo variants and the need to combine DNA and RNA data in some cases. This requires a unique set of interpretation tools and specifically tuned ...
based in, INDIA
inDNA Research Labs is an early stage big-data analytics healthcare startup that is at the forefront of trying to bring comprehensive genomic analysis to routine clinical care. Our goal is to democratize the use of genomics technologies by ...
OncoNGx Genomic Workbench is a HIPAA compliant cloud based informatics and clinical annotation platform that will translate sequence (NGS) data from a Cancer diagnostic gene panel into actionable report/information for ...
based inPalo Alto, CALIFORNIA (USA)
Lucence is a precision oncology company committed to bringing clarity to cancer care. Lucence makes ultrasensitive non-invasive liquid biopsy tests to provide doctors and their patients life-changing information to enable earlier detection and ...
LiquidHALLMARK® is an ultrasensitive next-generation sequencing assay for genomic profiling of a patient’s unique cancer. By requiring only a single blood sample, LiquidHALLMARK provides important information for cancer care especially ...
based inMarseille Cedex 9, FRANCE
Veracyte, formerly HalioDx, is a global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. Our ...
From our proprietary biomarkers, our innovated assays solutions, our unique data analysis platforms and our CDx development capabilities, we offer a comprehensive family of biomarker services that enhance your insight into the tumor microenvironment ...
based inMilford, MASSACHUSETTS (USA)
SeraCare is a leading partner and supplier of diagnostic quality controls, biological materials, and reagents to in vitro diagnostics developers, clinical laboratories, and life science researchers worldwide. Since the early 1980s, we have supported ...
The Seraseq Tumor Mutation DNA Mix v2 (AF7) HC is a multiplexed mixture of actionable biosynthetic DNA targets precisely blended with a single, well-characterized genomic background. This product is produced under ...
based inAustin, TEXAS (USA)
Natera is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more ...
Signatera is a personalized, tumor-informed assay optimized to detect circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment and recurrence monitoring for patients previously diagnosed with cancer, with broad utility for ...
based inChicago, ILLINOIS (USA)
Tempus is making precision medicine a reality through the power and promise of data and artificial intelligence. With the world’s largest library of clinical and molecular data, and an operating system to make that data accessible and useful, we ...
Tempus xE (version 2) is a whole exome next-generation sequencing assay that analyzes the entire coding region (exome) of the patient’s genome, combined with whole transcriptome RNA sequencing. Clinical sequencing is performed to 500x depth of ...